Publication
Article
Author(s):
This supplement to The American Journal of Managed Care describes the results of a post hoc analysis designed to evaluate attainment of diabetes-related quality measures with canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg in patients with type 2 diabetes mellitus. This information may be relevant to stakeholders increasingly focused on quality measures and population health management, such as payers, healthcare delivery organizations, and clinicians.This supplement was supported by Janssen Pharmaceuticals, Inc.
This analysis was funded by Janssen Scientific Affairs, LLC. Editorial support was provided by Bilge Yoruk, PhD, of Excerpta Medica, and was funded by Janssen Scientific Affairs, LLC.
Faculty
Robert A. Bailey, MD
Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey
Lawrence Blonde, MD
Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana
Gary E. Meininger, MD
Vice President, Franchise Medical Leader
Janssen Research and Development, LLC
Raritan, New Jersey
Marcia F.T. Rupnow, PhD
Senior Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey
Ujjwala Vijapurkar, PhD
Associate Director
Janssen Research and Development, LLC
Raritan, New Jersey
Faculty Disclosures
These faculty report relationships with the following organizations:
Robert A. Bailey, MD
Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Stock ownership: Johnson & Johnson
Lawrence Blonde, MD
Grants: Eli Lilly and Company, Novo Nordisk, and sanofi-aventis
Honoraria: AstraZeneca, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, Novo Nordisk, Quest Diagnostics, and sanofi-aventis
Gary E. Meininger, MD
Employment: Janssen Research and Development, LLC
Stock ownership: Johnson & Johnson
Marcia F. T. Rupnow, PhD
Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Stock ownership: Johnson & Johnson
Ujjwala Vijapurkar, PhD
Employment: Janssen Research and Development, LLC
Stock ownership: Johnson & Johnson
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.